STUDY PROTOCOL

Metabolic gestational age assessment in low resource settings: a validation protocol [version 1; peer review: 3 approved]

A. Brianne Bota¹, Victoria Ward², Stephen Hawken¹, Lindsay A. Wilson¹, Monica Lamoureux³, Robin Ducharme¹, Malia S. Q. Murphy¹, Kathryn M. Denize³, Matthew Henderson³, Samir K. Saha⁴, Salma Akther⁴, Nancy A. Otieno⁵, Stephen Munga⁵, Raphael O. Atito⁵, Jeffrey S. A. Stringer⁶, Humphrey Mwape⁷, Joan T. Price⁶, Hilda Angela Mujuru⁸, Gwendoline Chimhini⁸, Thulani Magwali⁹, Louisa Mudawarima⁸, Pranesh Chakraborty³, Gary L. Darmstadt², Kumanan Wilson¹

¹Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, ON, Canada
²Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
³Newborn Screening Ontario, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada
⁴Child Health Research Foundation, Mizapur, Bangladesh
⁵Kenya Medical Research Institute (KEMRI), Center for Global Health Research, Kisumu, Kenya
⁶Department of Obstetrics and Gynecology, UNC School of Medicine, Chapel Hill, NC, USA
⁷UNC Global Projects Zambia, Lusaka, Zambia
⁸Department of Paediatrics and Child Health, University of Zimbabwe, Avondale, Zimbabwe
⁹Department of Obstetrics and Gynaecology, University of Zimbabwe, Avondale, Zimbabwe

Open Peer Review

Reviewer Status

Invited Reviewers

| 1 | 2 | 3 |
|---|---|---|
| Tina M. Slusher ID, University of Minnesota, Minneapolis, USA
| Hennepin Healthcare, Minneapolis, USA|

Abstract

Preterm birth is the leading global cause of neonatal morbidity and mortality. Reliable gestational age estimates are useful for quantifying population burdens of preterm birth and informing allocation of resources to address the problem. However, evaluating gestational age in low-resource settings can be challenging, particularly in places where access to ultrasound is limited. Our group has developed an algorithm using newborn screening analyte values derived from dried blood spots from newborns born in Ontario, Canada for estimating gestational age within one to two weeks. The primary objective of this study is to validate a program that derives gestational age estimates from dried blood spot samples (heel-prick or cord blood) collected from health and demographic surveillance sites and population representative health facilities in low-resource settings in Zambia, Kenya, Bangladesh and Zimbabwe. We will also pilot the use of an algorithm to identify birth percentiles based on gestational age.
estimates and weight to identify small for gestational age infants. Once collected from local sites, samples will be tested by the Newborn Screening Ontario laboratory at the Children's Hospital of Eastern Ontario (CHEO) in Ottawa, Canada. Analyte values will be obtained through laboratory analysis for estimation of gestational age as well as screening for other diseases routinely conducted at Ontario’s newborn screening program. For select conditions, abnormal screening results will be reported back to the sites in real time to facilitate counseling and future clinical management. We will determine the accuracy of our existing algorithm for estimation of gestational age in these newborn samples. Results from this research hold the potential to create a feasible method to assess gestational age at birth in low- and middle-income countries where reliable estimation may be otherwise unavailable.

**Keywords**
gestational age, newborn screening, preterm birth, machine learning, prediction modeling

---

**Corresponding author:** Kumanan Wilson (kwilson@ohri.ca)

**Author roles:**
- **Bota AB:** Investigation, Project Administration, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing
- **Ward V:** Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing
- **Hawken S:** Conceptualization, Formal Analysis, Investigation, Software, Writing – Review & Editing
- **Wilson LA:** Conceptualization, Investigation, Project Administration, Writing – Review & Editing
- **Lamoureux M:** Investigation, Methodology, Project Administration, Writing – Review & Editing
- **Ducharme R:** Formal Analysis, Project Administration, Writing – Review & Editing
- **Denize KM:** Methodology, Project Administration, Writing – Review & Editing
- **Henderson M:** Conceptualization, Supervision
- **Akther S:** Investigation, Project Administration
- **Otieno NA:** Investigation, Project Administration, Supervision
- **Munga S:** Investigation, Writing – Review & Editing
- **Atito RO:** Investigation, Project Administration
- **Mwape H:** Investigation, Project Administration
- **Price JT:** Investigation, Supervision
- **Mujuru HA:** Investigation, Project Administration
- **Chakraborty P:** Conceptualization, Investigation, Resources, Supervision, Visualization
- **Darmstadt GL:** Conceptualization, Funding Acquisition, Methodology, Supervision, Visualization, Writing – Review & Editing
- **Wilson K:** Conceptualization, Funding Acquisition, Resources, Supervision, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** This work was supported by the Bill and Melinda Gates Foundation [OPP1184574 (KW) and OPP1182996 (GLD)]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Copyright:** © 2020 Bota AB et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Bota AB, Ward V, Hawken S et al. Metabolic gestational age assessment in low resource settings: a validation protocol [version 1; peer review: 3 approved] Gates Open Research 2020, 4:150
https://doi.org/10.12688/gatesopenres.13155.1

**First published:** 02 Oct 2020, 4:150 https://doi.org/10.12688/gatesopenres.13155.1
Background
Reliable estimates of gestational age are critical in determining population burden of preterm birth, and informing policies for resource allocation and prioritization of interventions in low resource settings. In many low- and middle-income countries, maternal access to quality antenatal care (ANC) may be limited. In particular, gestational dating ultrasound is not routinely available and thus gestational age is often estimated using less accurate methodologies such as date of last menstrual period (LMP), symphysis-fundal height or postnatal examination of the infant’s biophysical characteristics. The need for new methods to accurately assess gestational age in low resource settings has been identified as critical to ongoing efforts to improve global data on the burden of preterm birth.

In addition, accurate estimates of gestational age allow for distinction between preterm infants and those who are small for gestational age (SGA). This is an important difference when allocating resources for maternal and infant healthcare and ensuring the availability of appropriate interventions. The medical needs and achievement of developmental milestones may significantly differ between preterm and SGA infants; thus, accurately identifying at-risk infants at birth is important for informing the course of their postnatal care.

One component of our research group has developed a metabolic gestational age algorithm using biomarker data obtained from routine newborn metabolic screening in a cohort of nearly 150,000 infants born in Ontario, Canada. This approach has been previously validated in cohorts in Bangladesh and Zambia. In the Bangladeshi cohort, the model correctly estimated ultrasound-validated gestational age to within one week in the majority of infants, and within two weeks in 90–95% of infants using heel prick and cord blood metabolomic markers. We have since developed and internally validated a second generation of models using a machine learning algorithm and have conducted external validation of model performance in newborn data from two cohorts from Zambia and Bangladesh. The successful use of cord blood in estimating gestational age is of particular interest as we encountered barriers to heel prick sample collection in these populations. In particular, it was difficult to collect the heel prick sample in the recommended 24–72 hour window due to early hospital discharge. We also encountered parental reluctance to subject their infants to a heel prick sample collection, especially in preterm infants.

While our previous work, and that of others, suggests potential value in using dried blood-spot-derived analytes for gestational age assessment, some key questions need to be answered before attempting to utilize this approach widely as a surveillance tool for preterm birth:

- Is the approach feasible for implementation at primary birthing facilities in low-resource settings?
- Does application of the approach at primary birthing facilities provide an accurate estimate of the preterm birth rate in the population?
- What is the accuracy of metabolic gestational age assessment using cord blood relative to infant heel-prick blood?
- Can the approach distinguish SGA from appropriate-for-gestational age (AGA) and large-for-gestational age (LGA) infants?
- Can the performance of the algorithm be enhanced by including additional measures, such as anterior lens vascularity assessment, Ballard scoring, and anthropometric measurements?

Methods
Objectives
The goal of this study is to pilot a program that derives gestational age estimates from dried blood spot samples (heel-prick or cord blood) collected from a population-representative cohort in health and demographic surveillance sites in low-resource settings.

If successful, this will achieve the following objectives:

Primary objectives

1. Assess the feasibility of large-scale implementation of metabolic gestational age screening.
2. Estimate population-level burdens of preterm birth within select low-resource areas.

Secondary objectives

1. Estimate population-level burdens of SGA infants within low-resource settings through validation of a newly developed algorithm that simultaneously classifies infants as SGA/AGA/LGA while estimating gestational age.
2. Estimate population-level burdens of treatable, rare metabolic diseases.
3. Identify and treat infants at risk for these treatable life-threatening/altering metabolic diseases.
4. Generate a large international newborn metabolic dataset that could be leveraged for future preterm birth research.

At a population level, utilization of metabolic analysis for gestational age dating could support surveillance of the burden of preterm birth and research into the development
of effective resource management strategies. We will seek to determine whether this is feasible in low- and middle-income settings.

Ethics approval
This study was approved by the Ottawa Health Sciences Network Research Ethics Board (20180330-01H), Children’s Hospital Of Eastern Ontario Research Ethics Board (18/58X), the Stanford University School of Medicine Institutional Review Board (44656), the Kenya Medical Research Institute Scientific and Ethics Review Unit (SSC 2880), the University of Zambia Biomedical Research Ethics Committee (015-06-17), the Bangladesh Institute of Child Health (BICH-ERC-01-01-2019), and the Research Council of Zimbabwe (03744).

Project funding
The Ottawa Hospital Research Institute (OHRI) has received funding from the Bill & Melinda Gates Foundation to cover project coordination costs in Ontario, Canada, including but not limited to sample analysis, gestational age estimation model execution and project management (OPP1184574). Stanford University received funding from the Bill & Melinda Gates Foundation to operationalize the project including site selection, protocol training, subcontracting to international sites, oversight and communication with international sites (OPP1182996).

Study setting
This project is led by the OHRI with services provided by Newborn Screening Ontario (NSO), in partnership with the Department of Pediatrics, Stanford University and supported by the Bill & Melinda Gates Foundation. Sample collection sites include: Mirzapur, Bangladesh led by the Child Health Research Foundation; Kisumu, Kenya led by a team from the Kenya Medical Research Institute (KEMIR) and Center for Disease Control and Prevention (CDC) collaboration; Lusaka, Zambia led by UNC-GPZ; and Harare, Zimbabwe led by researchers from University of Zimbabwe.

Site selection
Investigators at Stanford University were responsible for identifying and training international partners in sample collection at facilities located in South Asia and sub-Saharan Africa. Identification of eligible site partners was based on capacity for sample collection from population representative cohorts and the ability to collect samples from both hospital and primary birthing facilities in order to evaluate whether metabolic gestational age dating approaches were valid estimates of population-level preterm birth rates.

We evaluated 19 sites for inclusion in the study. Sites were deemed acceptable if they met the following specific criteria: early pregnancy registration, ultrasound capacity, ability to obtain newborn heel-prick and cord blood samples, capacity to store and ship blood spot cards and cord blood samples, ability for patient follow up and demographic surveillance, and ability for follow-up testing for screen positive results for treatable metabolic diseases. Four sites were identified that broadly met our inclusion criteria. All sites were trained on cord blood and heel-prick derived dried blood spot collection.

Sites
Mirzapur, Bangladesh. The Child Health Research Foundation is a demographic surveillance site (DSS) with births occurring at the Kumudini Hospital, local clinics, and at home. The DSS sites covers 374 km², with a population of close to 300,000 people. One data collector covers approximately 400 households and visits every four months to collect demographic information. The preterm birth rate at this site is estimated to be 18–19% based on LMP. Half of the study population will be enrolled at the time of birth at the birthing center at the Kumudini Hospital, and half will be enrolled at 20 weeks’ gestation through the DSS to allow for first trimester ultrasound validation. Women enrolled at 20 weeks gestation will be transported to Kumudini Hospital for ultrasound examination. Heel prick samples will be collected for all infants, and cord blood samples will also be collected for infants born at Kumudini Hospital. An estimated 840 cord and 1455 heel prick samples will be collected from this site over an estimated 12-month period.

Kisumu, Kenya. The Kenya research center is located in Kisumu, at the KEMRI Center for Global Health Research. Field research sites are located in Siaya county where a maternal-infant surveillance platform hosting a prospective cohort of pregnant women and their infants is implemented from two community hospitals; Siaya County Referral Hospital (SCRH) and Bondo sub-County Hospital (BSCH). The SCRH is the main referral hospital for the county region. Bondo Hospital, located 23 km south, serves as a primary birthing center and enrollment site for the community. Participants are enrolled at their first ANC visit or by research nurses or through trained community health workers (CHWs) who administer home-based urine pregnancy testing and refer pregnant women to the study clinics for further screening and enrollment. Eligible participants at this site include pregnant women 15–49 years of age, coming from a 10 km radius of the research facility, willing to deliver in the research hospital and not planning to relocate/migrate within one year of enrollment into the surveillance program. Women are typically enrolled prior to 20 weeks’ gestation at which time they undergo ultrasound, and are offered treatment for common illnesses including malaria, urinary tract infections and sexually transmitted infections. It is expected that 10% of babies will be born at home, with infants evaluated within 72 hours. Prior studies have estimated the preterm birth rate to be 19% by a combination of LMP and ultrasound. Expected enrollment is approximately 780 cord and heel samples with paired ultrasounds for all women collected over one year.

Lusaka, Zambia. Building on prior work of our pilot project nested in the ZAPPS-1 study, we partnered with UNC-GPZ to implement metabolic analysis for the participants of two existing study cohorts: the Zambian Preterm Birth Prevention Study (ZAPPS-2) and Improving Pregnancy Outcomes with Progesterone (IPOP). All enrollees are recruited prior to 24 weeks’ gestation in this cohort, and ultrasound occurs at the time of enrollment. Inclusion criteria for ZAPPS-2 and IPOP are women 18 years of age or older, residing in Lusaka with no plans to relocate. Women in the ZAPPS-2 cohort are HIV uninfected, whereas women enrolled in the IPOP study are HIV-1...
positive and receiving antiretroviral therapy, HIV status and anti-retroviral therapy will be accounted for in the analysis phase. Enrollment occurs over eight district clinics with delivery in the Lusaka University Hospital, creating a population representative sample for peri-urban Zambian women. This site has an estimated preterm birth rate of 15% by ultrasound\(^1\). The goal sample size for this site is estimated to be 600 cord and heel samples, all paired with ultrasound. Sample collection is expected to occur over one year.

**Harare, Zimbabwe.** The Zimbabwe site consists of two primary birthing clinics and the referral hospital with a large volume of community and hospital deliveries. The estimated preterm birth rate is 12% based on LMP. Most pregnancies are registered after 24 weeks of gestation. Ultrasound is not routinely available unless complications are identified or by self-pay in a private clinic. Extensive laboratory capacity exists for follow-up testing of screen positive results; however, mass spectrometry is not available. Half of participants in the Zimbabwe cohort will be enrolled at birth from the referral hospital and half will be enrolled during their first ANC visit at primary care clinics, at which time they will undergo ultrasound, yielding a total sample size of approximately 1000 participants. Participants enrolled at primary care clinics will be transferred to the referral hospital if they go into preterm labour. We expect sample collection to occur over nine months.

**Patient consent**
At all sites, parental informed consent will be sought prior to enrollment in the study, and consent forms will be available in local languages. All liveborn infants will be eligible for inclusion in this study. Women will be enrolled by research nurses during the first ANC visit or at delivery (depending on site enrollment criteria). Participants will be made aware that participation is voluntary, and the risks and benefits of enrollment will be discussed. Those choosing not to participate will continue to receive ANC and treatment according to local clinical standards. Participants will be assured that all reasonable measures will be taken to protect their personal information and that of their newborn. Participants enrolled at the Bangladesh, Zambia, and Kenya sites will also consent to storage and future use of their samples for perinatal research under authorization of presiding institutional committees.

Consenting parents will be informed that heel-prick collection may cause temporary discomfort to their newborn and will also be informed of the possibility that their child may be identified to be at risk of one or more treatable metabolic conditions. Participants will be informed that such incidental findings will be communicated to the study investigators and recommendations will be made to confirm diagnoses and help guide any necessary treatment of their infant. At the time of consent, participants will be informed of their right to request the full details of the screening results for their newborns.

**Collection of newborn screening specimens**
Study personnel will collect, handle and transport heel-prick and cord dried blood spot samples from participants according to study-specific standard operating procedures (Figure 1). Sample collection procedures have been published previously\(^2\). In brief, cord blood will be collected within 30 minutes of delivery of the placenta into an uncoated, sterile syringe. Blood from the syringe (4–5 drops) will be applied to designated filter paper within pre-printed circles. Newborn heel-prick samples will be collected ideally between 24–72 hours after birth or prior to discharge if the newborn is released from hospital within 24 hours of delivery. The newborn’s heel will be warmed at the identified skin-puncture site to promote increased blood flow. The puncture site will be cleaned and air-dried. A sterile lancet or heel incision device will be used to puncture the lateral aspect of the plantar surface of the newborn’s heel. The first small drop of blood formed will be cleaned away and the formation of a second large drop of blood will be encouraged by intermittently applying gentle pressure to the newborn’s lower leg and heel. A filter card will be applied gently against the blood drop to soak through. Each preprinted circle on the filter card will be filled by subsequently formed drops of blood. Following heel-prick sample collection, the newborn’s foot will be elevated above the body and a sterile gauze pad or cotton swab will be pressed against the puncture site until the bleeding stops. No more than 500µL of blood of each sample type (heel prick or cord) will be required for this study. To reduce newborn discomfort during the heel prick sample collection, mothers will be encouraged to hold the baby close or breastfeed the baby before and during the procedure.

Labels with unique site-specific de-identified participant identifiers (ID) will be affixed to each filter card at the time of collection. Samples will be air-dried for 3–4 hours or overnight after which they will be transported to a designated secure study location (hospital office or laboratory) and stored in a room temperature setting prior to shipping. Samples will be shipped at room temperature from the collection sites to NSO every seven days by a preferred courier service. We have previously found samples to be stable for up to two months at room temperature in climate-controlled conditions\(^3\). Appropriate shipping standards will be communicated to the collection sites to minimize the risk of compromised sample integrity during shipping.

An electronic shipment manifest containing clinical and demographic information essential for clinical interpretation of newborn metabolic profiles will be relayed to NSO and OHRI ahead of shipping and included as a hard copy in the shipment (Table 1). Upon receipt of the samples at NSO, the sample manifest will be cross-referenced against the physical sample cards. Any discrepancies will be resolved through follow-up with the collection site. Secondary accession numbers will be applied for use by internal NSO systems.

**Newborn screening analysis**
NSO is Ontario’s provincial newborn screening program, located at the Children’s Hospital of Eastern Ontario Research Institute (CHEO RI). All samples collected will be directed to NSO for laboratory analysis. NSO is equipped with sufficient personnel and laboratory resources to accommodate the inclusion of international clinical and research samples into the organization’s standard workflow. The organization is currently providing newborn screening services to remote communities in

---

\(^1\) Gates Open Research 2020, 4:150 Last updated: 16 AUG 2021

---
Figure 1. Study Workflow. Participants are enrolled in the research study, and samples collected at the collection sites are sent weekly via preferred courier to Newborn Screening Ontario (NSO), Ottawa Canada for analysis. Reporting procedures from the NSO to the collection site include provision of reports on sample quality, on newborns' risk of congenital hypothyroidism (CH), medium-chain acyl-CoA dehydrogenase deficiency (MCADD) and haemoglobinopathies (HGBs) and quarterly reports summarizing study progress. Adapted from 12 under a CC BY 4.0 license. ANC, antenatal care; DBS, dried blood spot; NSO, Newborn Screening Ontario; CH, congenital hypothyroidism; HGB, hemoglobinopathies; MCADD, medium-chain acyl-CoA dehydrogenase deficiency.
### Table 1. Data variables required to support newborn screening analysis.

| Variable                                      | Values                                                                 |
|-----------------------------------------------|------------------------------------------------------------------------|
| De-identified participant ID                  |                                                                        |
| Sample type                                   | Cord or heel                                                           |
| Application method to filter card             | Direct, tube, syringe                                                  |
| Sex                                           | Male, female, ambiguous                                                |
| Birthweight                                   | grams                                                                  |
| Multiple birth                                | Yes/no; if yes, baby 1, 2, 3 or a, b, c                                |
| Feeding status                                | Breast, TPN, formula, NPO                                              |
| Packed red blood cell transfusion             | Yes/no: if yes, date of latest transfusion                            |
| Gestational age                               | If available; weeks + days                                            |
| Date and time of birth                        |                                                                        |
| Date and time of sample collection            |                                                                        |

TPN, total parenteral nutrition; NPO, nil per os (nothing by mouth).

Quality management of samples
NSO will refer to organization and international standards to guide quality management of samples\[^{15,16}\]. Each sample received will be reviewed for specimen quality and quantity. Newborn screening test calculations assume that the blood is evenly distributed within the circle and completely saturates both sides of the filter paper, and so a satisfactory newborn screening specimen will have blood fully soaked through to the back of the filter paper. Only satisfactory samples will be used for study analysis. Samples can be deemed unsatisfactory for several reasons as outlined in Table 2. If the sample quality is unsatisfactory due to insufficient quantity of blood, the sample will be excluded from analysis or undergo partial analysis.

NSO will generate Quality Reports summarizing the quality of samples received in each shipment. These reports will be sent electronically to the collection site and used to address issues of sample collection, handling and storage prior to shipment. The Report will summarize the Batch ID for the batch of samples received, specimen details and the quality of the samples, as outlined in Table 2.

Sample analysis
Standard practice at NSO is to screen each sample for metabolites indicative of risk for approximately 30 treatable conditions. Full-panel analyses as per standard NSO practice will be executed on samples when sample quality is satisfactory.

Quarterly reporting
Quarterly Reports summarizing study progress will be generated by NSO and electronically shared with the study sites, Stanford University and OHRI. Quarterly Reports will include a summary of the analytical results collected up to the end of that quarter, and summarize the total number of samples received, sample collection data (time of collection), newborn characteristic data (gestational age, sex, multiple birth etc.) and the number and distribution of samples excluded from analysis based on ‘unsatisfactory’ quality.

Management of incidental findings
The conditions screened as part of the NSO screening panel are extremely rare. It is possible that an infant will be identified to be at high risk for one of these screened conditions through sample analysis. Such risk poses clinical and ethical considerations for gathering newborn screening data for research purposes. While this study involves newborn screening, this study is not being undertaken as a newborn screening initiative and is designed explicitly as a non-interventional study.

Real time notification of incidental findings will be made for conditions that can be feasibly treated at the collection sites. Sample integrity, potential for confirmatory testing and potential for intervention were all taken into consideration when determining the feasible management of incidental findings, and our approach and rationale have been described in detail elsewhere\[^{6,12,17}\]. Based on the above considerations, three high-priority conditions have been identified for real-time reporting: congenital hypothyroidism (CH), hemoglobinopathies, and medium-chain acyl-CoA dehydrogenase deficiency (MCADD).

other Canadian provinces/territories, and has piloted international screening services\[^{14}\].

[^15]: [Reference](#)
[^16]: [Reference](#)
[^17]: [Reference](#)
In brief, in the event that an infant screens positive for a priority condition, second-tier analysis of samples, including repeat confirmatory testing, CFTR mutation analyses, TBX1 and purine profile assays, will be executed as per a modified workflow based on standard NSO practice, provided sufficient sample is available from the original blood spot card. Electronically encrypted Alert Reports will be provided as soon as analysis is complete, and the screening results have been interpreted. The Alert Report will indicate the disease for which the infant is at high risk, the flagged analyte, the analyte level, and the reference ranges and thresholds for the flagged analyte. To ensure that communication of clinically relevant findings between investigators is successful, the collection site will confirm receipt of all Alert Reports within 24 hours. The report will recommend that positive screen results be communicated to the participant’s family, and that appropriate follow-up testing be conducted along with any necessary medical intervention, implemented in accordance with local treatment guidelines. The collection site will report back to the lead site with a completed Alert Report identifying confirmatory testing and medical follow-up.

Data management

Upon completion of sample collection, sites will provide OHRI and Stanford with a detailed data collection form with maternal and neonatal covariates required for model validation and analysis (Table 3). The data will be paired with matching newborn screening data provided by NSO into a single, combined dataset to be used for analysis. Once the primary analytic goals of the project have been met, these data will be stripped of patient identifiers and made available as a shared dataset by site and shared with the appropriate participating institutions in the pursuit of open collaborative research. A common data use agreement will be generated to govern the sharing and use of the data.

The research team at the Ottawa Hospital Research Institute (OHRI) will lead primary data analyses for the generation of gestational age, preterm birth and SGA estimates, and all regulatory activities required at OHRI and CHEO RI, including but not limited to research contracts, data/material sharing agreements and ethics approvals. Each site will be provided with copies of their own cohort data for use in future analyses in consultation with the overall group.

Statistical analysis

Model-based gestational age estimation and classification of preterm birth, SGA/AGA/LGA using clinical covariates and newborn screening metabolites. Newborn gestational age will be estimated from models derived using multivariable regression coupled with elastic net regularization and including the following covariates:

1. Model 1: Birth weight, sex, multiple birth status and pairwise interactions
2. Model 2: Sex, multiple birth status, newborn screening analytes and pairwise interactions
3. Model 3: Birth weight, sex, multiple birth status and newborn screening analytes

Classification of preterm birth, as well as SGA/AGA/LGA is conducted using an iterative multitask classification machine learning algorithm that simultaneously derives classification models for both preterm birth status and SGA/AGA/LGA and

| Parameter of sample quality | Quality   | Action for analysis |
|----------------------------|-----------|---------------------|
| Acceptable                 | Satisfactory | Include             |
| Blood spot collection paper expired | Unsatisfactory | Exclude             |
| Blood spots appear clotted or layered | Unsatisfactory | Exclude             |
| Blood spots appear diluted  | Unsatisfactory | Exclude             |
| Blood spots appear scratched or abraded | Unsatisfactory | Exclude             |
| Blood spots appear damaged  | Unsatisfactory | Exclude             |
| Blood spots are supersaturated | Unsatisfactory | Exclude             |
| Blood spots are wet/discoloured | Unsatisfactory | Exclude             |
| Blood spots exhibit serum rings | Unsatisfactory | Exclude             |
| Quantity of blood insufficient | Unsatisfactory | Review decision*   |

* If the sample quality is unsatisfactory due to the insufficient quantity of blood, the sample will be reviewed at time of receipt and will be excluded from analysis or undergo partial analysis.

Table 2. Sample quality screening criteria.
uses the prediction of one to inform the prediction of the other. These models include birthweight, sex, multiple birth status and newborn screening analytes as predictors, similar to Model 3 above. The model classifying preterm birth status will also use the prediction of SGA/AGA/LGA from the other model, and vice versa, improving the accuracy of both predictions, and will also employ an elastic net or lasso regularization approach similar to gestational age estimation models.

Models were trained and internally validated in independent training and validation/test cohorts of infants from Ontario, Canada. These pretrained models can then be applied to the data for infants from the external cohorts to produce gestational age estimates. In order to evaluate the accuracy of gestational age estimates calculated from the models, the model estimate will be compared to the ultrasound reference gestational age for each infant, and the residual error calculated (model gestational age minus reference gestational age). These residuals can be squared, absolute value taken, summed and averaged to calculate different metrics including: mean square error (MSE); standard error of estimation, also known as root mean square error (RMSE); and mean absolute error (MAE), which is the average of the absolute value of the residual across all subjects (or subsets of subjects). Additionally, we will calculate the proportion of model-derived estimates that fall within ± 1 and ± 2 weeks of reference ultrasound gestational age for those samples with gestational age available. MAE will be the main performance metric we will use to evaluate model accuracy, but multiple metrics will be calculated and reported to facilitate comparisons to other models developed by our group and others. Model-derived frequency of preterm birth will be compared to the preterm birth frequency based on reference ultrasound gestational age by dichotomizing the model and reference gestational age values, where preterm is defined as gestational age <37 weeks and term is defined as gestational age ≥37 weeks.

For classification models predicting preterm birth status and SGA/AGA/LGA, we will report area under the ROC curve, as well as sensitivity/specificity and positive predictive values. We will assess model calibration by constructing and visually inspecting calibration plots of and through calculation of the calibration slope and intercept for a regression of model gestational age vs. reference gestational age, and for predicted vs actual probabilities of preterm birth and SGA/AGA/LGA for classification models.

**Assessment of other gestational age measures.** We will collect additional assessments of gestational age, including anterior lens vascularity, Ballard score, anthropometric measures, LMP and

| Neonatal characteristics | Date of ANC-1 ultrasound |
|--------------------------|--------------------------|
|                          | Gestational age at time of ultrasound (weeks + days) |
|                          | Birth weight (grams) |
|                          | Gestational age (weeks + days) |
|                          | Date and time of birth |
|                          | Date and time of sample collection |
|                          | Feeding status (breast, TPN, formula, NPO) |
|                          | Transfusion (yes, no; if yes, date of latest transfusion) |
|                          | Multiple births (yes, no; if yes, baby a, b, c or 1, 2, 3) |
|                          | Low birth weight, intrauterine growth restricted, small- or large-for-gestational age |
|                          | Mode of delivery (Caesarian section, vaginal: spontaneous, practitioner induced) |
|                          | Presentation at time of delivery |
|                          | Apgar scores |
|                          | ALCV image capture |
|                          | Ballard score |

| Maternal characteristics | Age (years) |
|--------------------------|-------------|
|                          | Body mass index (weight (kg)/ (height (m))^2) |
|                          | Parity and gravidity |
|                          | Smoking status |
|                          | Alcohol consumption (if available) |
|                          | Diabetes |
|                          | Hypertension |
|                          | HIV status (if known) |
|                          | Viral load (if applicable) |

ANC, antenatal care; TPN, total parenteral nutrition; NPO, nil per os (nothing by mouth); ALCV, anterior lens capsule vascularity.

---

Table 3. Maternal and neonatal covariates to be included for the study.
first trimester ultrasound to compare the accuracy of gestational age estimates with our algorithm.

Dissemination
Knowledge Translation will be facilitated through the relationships between researchers, funding organization, and the communities involved in the project. Our findings will be disseminated through publication in peer-reviewed Open Access journals and presentations at academic conferences. We will promote awareness of our findings through press release within our institutions, locally and abroad. The data is collectively owned by OHRI, CHEO and Stanford. Third party de-identified data sharing is possible with the expressed written agreement of all applicable parties and with the development of the appropriate Data Sharing Agreements.

Study status
All ethics approvals and contracts are in place between all partners. NSO began receiving samples from Zambia, Bangladesh and Kenya in April 2019 and sample collection is nearing completion at these sites. For Kenya and Bangladesh we have not observed the same hesitancy to perform heel prick blood sampling as in our previous studies. Sample collection in Zimbabwe was planned to start in March 2020 but study initiation was delayed due to the COVID-19 global pandemic.

Impact of the project
Preterm birth continues to be a leading cause of mortality in children under five and being born too early or too small has long-term health and economic consequences. Accurate estimates of the population burden of preterm birth are critical to inform resource allocation and prioritize interventions for preterm birth. This project will provide critical insight into the feasibility of the large-scale implementation of metabolic gestational age screening in low resource settings and will inform the logistical requirements and feasibility of scaling up our protocol and algorithms for population surveillance of preterm birth and SGA estimates in low-resource settings.

By comparing estimates obtained from primary birthing centers and DSS, insights will be gained into the feasibility of obtaining accurate estimates of population-level preterm birth rates through enrollment at primary birthing centers. We will also compare the accuracy of estimates of gestational age derived from cord blood samples and infant heel-prick samples, which will be important for accommodating local preferences for specimen collection method in future studies.

This project will also generate a large international database of newborn screening data that could be leveraged for future preterm birth research.

Our protocol for screening of certain diseases will both inform on the prevalence of these conditions and identify and treat afflicted infants for potentially life-threatening/life altering conditions that would have otherwise gone undiagnosed. In our previous prospective cohort study, 61 infants were identified with congenital hypothyroidism and hemoglobinopathies in a cohort of 1661 samples from a rural community in Bangladesh. In the current cohorts, diagnostic capabilities and treatment are available at all sites. Screening cut-offs are set higher for international sites compared to normal NSO diagnostic criteria to allow for blood spot screening to have a high positive predictive value.

At present, options for the treatment of either SGA or preterm infants remain limited in low- and middle-income countries. The inability to distinguish preterm and SGA infants due to unreliable gestational age estimation precludes different treatment strategies for these two populations. Interventions, such as Kangaroo-Mother Care, are targeted at low birth weight infants and thus likely capture both SGA and pre-term infants. Better distinction between these two populations in low-resource settings could contribute to more targeted approaches and potentially better outcomes.

Finally, this study will also inform the proper sample handling, storage and processing procedures for accurate assessment of preterm birth and newborn screening and thus could inform the feasibility for implementing newborn screening practices in low-resource settings either on site or with international partners.

In summary, this protocol provides details on an important prospective cohort study to estimate gestational age in low resource settings and will provide valuable insight into the utility of newborn screening analytes in evaluating preterm birth rates in low-resource settings.

Data availability
No data are associated with this article.

References
1. Lee AC, Mullany LC, Ladhan K, et al.: Validity of Newborn Clinical Assessment to Determine Gestational Age in Bangladesh. Pediatrics. 2016; 138(1): e20153303. PubMed Abstract | Publisher Full Text | Free Full Text
2. Quinn JA, Munoz FM, Gonik B, et al.: Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2016; 34(49): 6047-56. PubMed Abstract | Publisher Full Text | Free Full Text
3. Neufeld LM, Haas JD, Grajeda R, et al.: Last menstrual period provides the best estimate of gestation length for women in rural Guatemala. Paediatr Perinat Epidemiol. 2000; 20(4): 295-8. PubMed Abstract | Publisher Full Text
3. Wilson K, Hawken S, Ducharme R, et al.: Metabolomics of prematurity: analysis of patterns of amino acids, enzymes, and endocrine markers by categories of gestational age. Pediatr Res. 2014; 75(2): 367–73. PubMed Abstract | Publisher Full Text

4. Murphy MSQ, Hawken S, Atkinson KM, et al.: Metabolic profiles derived from residual blood spot samples: A longitudinal analysis [version 1; peer review: 2 approved]. Gates Open Res. 2018; 2: 28. PubMed Abstract | Publisher Full Text | Free Full Text

5. Jelliffe-Pawlowski LL, Norton ME, Baer RJ, et al.: Gestational dating by metabolic profile at birth: a California cohort study. Am J Obstet Gynecol. 2016; 214(4): S11.e1–S11.e13. PubMed Abstract | Publisher Full Text | Free Full Text

6. Murphy MS, Hawken S, Cheng W, et al.: External validation of postnatal gestational age estimation using newborn metabolic profiles in Matlab, Bangladesh. eLife. 2019; 8: e4627. PubMed Abstract | Publisher Full Text | Free Full Text

7. Murphy MS, Hawken S, Vwalika B, Rittenhouse KJ, et al.: Postnatal gestational age estimation using newborn screening blood spots: a proposed validation protocol. BMJ Glob Heal. 2017; 2(2): e000365. PubMed Abstract | Publisher Full Text | Free Full Text

8. Price JT, Vwalika B, Rittenhouse KJ, et al.: Adverse birth outcomes and their clinical phenotypes in an urban Zambian cohort [version 2; peer review: 2 approved]. Gates Open Res. 2020; 3: 1533. PubMed Abstract | Publisher Full Text | Free Full Text

9. Castillo MC, Fuseini NM, Rittenhouse K, et al.: The Zambian Preterm Birth Prevention Study (ZAPPS): Cohort characteristics at enrollment [version 3; peer review: 2 approved]. Gates Open Res. 2018; 2: 25. PubMed Abstract | Publisher Full Text | Free Full Text

10. Price JT, Vwalika B, Freeman BI, et al.: Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOPP randomized trial. BMC Pregnancy Childbirth. 2019; 19(1): 81. PubMed Abstract | Publisher Full Text | Free Full Text

11. Murphy MSQ, Hawken S, Atkinson KM, et al.: Postnatal gestational age estimation using newborn screening blood spots: a proposed validation protocol. BMJ Glob Heal. 2017; 2(2): e000365. PubMed Abstract | Publisher Full Text | Free Full Text

12. Murphy MSQ, Hawken S, Atkinson KM, et al.: Postnatal gestational age estimation using newborn screening blood spots: a proposed validation protocol. BMJ Glob Heal. 2017; 2(2): e000365. PubMed Abstract | Publisher Full Text | Free Full Text

13. Hawken S, Ducharme R, Murphy MS, et al.: Measurement and Newborn Health. Reference Source

14. Wilson LA, Feil DB, Hawken S, et al.: Association between newborn screening analytes and hypoxic ischemic encephalopathy. Sci Rep. 2019; 9: 15704. Publisher Full Text

15. A GUIDE FOR NEWBORN CARE PROVIDERS Edition 2.1 | Newborn Screening Manual N ONATAL Newborn Screening Manual: A guide for newborn care providers Section 1 Background information 1.1 Introduction 1.2 NSO history 1.3 NSO contact information 1.4 Newborn screening essentials 1.5 Newborn screening timeline 1.6 Newborn screening results 1.7 List of diseases on the NSO newborn screening report. 2018. Reference Source

16. NB501-A6 Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard-Sixth Edition. 2013. Reference Source

17. Murphy MSQ, Chakraborty P, Pervin J, et al.: Incidental screen positive findings in a prospective cohort study in Matlab, Bangladesh: Insights into expanded newborn screening for low-resource settings. Orphanet J Rare Dis. 2019; 14: 25. Publisher Full Text

18. Liu L, Oza S, Hogan D, et al.: Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016; 388(10063): 3027-35. PubMed Abstract | Publisher Full Text | Free Full Text

19. Ota E, Ganchimeg T, Morisaki N, et al.: Risk factors and adverse perinatal outcomes among term and preterm infants born small-for-gestational-age: secondary analyses of the WHO Multi-Country Survey on Maternal and Newborn Health. PLoS One. 2014; 9(8): e105155. PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Peer Review Status: ✓ ✓ ✓

Version 1

Reviewer Report 22 January 2021

https://doi.org/10.21956/gatesopenres.14350.r30180

© 2021 Reis Z. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Zilma Silveira Nogueira Reis

Center of Health Informatics, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

This paper presents a study protocol to validate the metabolic gestational age assessment using cord blood relative to infant heel-prick blood in low-resource settings. Current challenges for gestational age assessment were described, as well as prior steps of this new approach. This feasibility study started already, expecting a large-scale implementation of metabolic gestational age screening. If it has not started, please inform the expected date.

Low-resources birth settings claim for prompt and easy-to-implement solutions with the potential to indicate neonatal risk, facing unknown or unreliable gestational age. I consider this program a possible response to such complaints.

My questions and suggestions:
1. Secondary objective number 3 is unclear to me - “Identify and treat infants at risk for these treatable life-threatening/altering metabolic diseases.” During the first 48 hours of life, very early blood samples are associated with false-negative screening for diseases as congenital hypothyroidism, phenylketonuria. Newborn heel-prick samples will be collected ideally before discharge, mostly within 24 hours of delivery. How will researchers deal with this issue?

2. How will the study conduct treatment of rare neonatal diseases screened in low-income countries?

   • Is the study design appropriate for the research question?

   ○ Yes, I consider the study design appropriate for the primary objective. I suggest the study registration in the WHO Clinical Trials Platform.

   • Are sufficient details of the methods provided to allow replication by others?

3. In methods, details of antenatal ultrasound assessment are not clear. Ultrasound dating
uses fetal size to determine gestational age based on the assumption that fetuses grow at the same rate in early pregnancy. Which fetal growth curve will be used, and who will assess fetuses with the ultrasound?

4. Regarding SGA, AGA, and LGA assessment using algorithms, what is the reference curve for fetal growth standardized in the study?

5. Ballard's score inter-observer error cannot be overlooked, and the exam demands health professional experience. How will the study reduce the bias of the observer's expertise?

6. About the sample size, is there any estimate to achieve significant results?

Is the rationale for, and objectives of, the study clearly described?
Yes

Is the study design appropriate for the research question?
Yes

Are sufficient details of the methods provided to allow replication by others?
Partly

Are the datasets clearly presented in a useable and accessible format?
Not applicable

Competing Interests: I declare the following competing interest - I am an inventor of a new medical device for gestational age estimate, using skin reflection. The intellectual property belongs to my University, and I am not involved with product commercialization. Patent register: US20200178847A1. This technology was supported by the BMG Foundation. I confirm that this has not affected my ability to write an objective and unbiased review of the article.

Reviewer Expertise: I am experienced in Maternal and Child Health, and Medical Informatics, acting on the following topics: medical informatics, scientific methodology, and women's health.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Division of Epidemiology & Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa

This manuscript describes the pilot testing of metabolic gestational age assessment using DBS in low-income settings. GA assessment is challenging in resource-limited settings where ultrasonography is typically unavailable and routinely based on clinical assessment; as such this manuscript addresses an important public health concern by presenting a potential option for GA assessment in low-income settings.

This is a well-written manuscript and I only have the following minor comments/queries:

**Background:**
- Repetition of the following paragraph: “while our previous work, and that of others, suggests potential value...widely as a surveillance took for preterm birth”.

**Methods:**
- Perhaps the authors could provide the target sample sizes for samples from each site - the justification/calculations for each site are not clear.
- Could there be standardization of language/structure of the site descriptions in terms of the site (which facilities), site's PTB rate, timing of enrolment, eligibility/inclusion criteria, sample size of samples vs participants?
- Site-specific comments:
  - **Bangladesh**
    - “...Kumudini Hospital, and half will be enrolled at 20 weeks gestation......to allow for first trimester ultrasound validation”
    - Were these women enrolled at 20 weeks or at 20 weeks or earlier - if the former perhaps first trimester ultrasound should be changed to early ultrasound.
  - **Kenya**
    - “Participants enrolled at their first ANC visit....”
    - Were women enrolled at this visit enrolled regardless of gestational age?
      - Linked to point above “Women are typically enrolled prior to 20 weeks gestation” - what is the procedure for late presenters? Are they enrolled? If yes do they have an ultrasound assessment?
  - **Zimbabwe**
    - Similar to the comment above are there any GA restrictions for women enrolled at first ANC visit?
    - “Yielding a total sample size of approximately 1000 participants”.
      - Does this mean the goal sample size is estimated to be 1000 heel and cord samples?

  - “Classification of preterm birth, as well as SGA/AGA/LGA....”
    - Which standards will be used for classification of size for gestation age - is it an international standard like INTERGROWTH-21st or regional standards?

**Is the rationale for, and objectives of, the study clearly described?**
Is the study design appropriate for the research question?
Yes

Are sufficient details of the methods provided to allow replication by others?
Yes

Are the datasets clearly presented in a useable and accessible format?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: perinatal epidemiology, maternal and child health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 19 Jan 2021
Kumanan Wilson, Ottawa Health Research Institute, Ottawa, Canada

This is a well-written manuscript and I only have the following minor comments/queries:

Background:
  ○ Repetition of the following paragraph: “while our previous work, and that of others, suggests potential value...widely as a surveillance took for preterm birth".

Response:
Thank you for noticing the paragraph repetition, it appears to be an error during publication.

Methods:
  ○ Perhaps the authors could provide the target sample sizes for samples from each site - the justification/calculations for each site are not clear.

Response:
We have added a subsection to the methods providing further details on the sample size calculations. The estimated sample size provided for each site is the target sample size for each population. For sample size requirements for an external validation, we followed the general philosophy and guidance of Steyerburg's Clinical Prediction Models. The estimated preterm birth rates at each site and number of ultrasounds that could reasonably be obtained were also considered. We were guided by a pragmatic target sample size of 20 observations in the smallest subgroup as this sample size is sufficient to calculate a robust summary (e.g. mean and CI) of the reported performance metrics in each subgroup of interest, for continuous GA, without requiring an unachievably large sample size. For example, if the rate of <34 weeks was 5%, this would require an overall sample size of n=400 (20/0.05) for that site.

This subsection is presented following the site selection section in the Methods.
  ○ Could there be standardization of language/structure of the site descriptions in terms
of the site (which facilities), site’s PTB rate, timing of enrolment, eligibility/inclusion criteria, sample size of samples vs participants?

**Response:**
We have structured the information, so it follows a similar pattern for each site – site details, estimated PTB, enrollment details, target sample size.

- Site-specific comments:
  - Bangladesh
    - “...Kumudini Hospital, and half will be enrolled at 20 weeks gestation.....to allow for first trimester ultrasound validation”
    - Were these women enrolled at 20 weeks or earlier - if the former perhaps first trimester ultrasound should be changed to early ultrasound.

**Response:**
Thank you, we have edited this to say 'enrolled at or before 20 weeks to allow for early ultrasound validation.'

- Kenya
  - “Participants enrolled at their first ANC visit....”
    - Were women enrolled at this visit enrolled regardless of gestational age?
      - Linked to point above “Women are typically enrolled prior to 20 weeks gestation” - what is the procedure for late presenters? Are they enrolled? If yes do they have an ultrasound assessment?

**Response:**
At this site, participants are typically enrolled prior to 20 weeks. Some participants are enrolled outside of the recommended range. All participants enrolled undergo ultrasound, and the date of ultrasound will be considered during analysis.

- Zimbabwe
  - Similar to the comment above are there any GA restrictions for women enrolled at first ANC visit?

**Response:**
Ultrasound enrollment target is <20 weeks, however enrollment beyond this gestational age may occur if this is necessary to achieve sample size goals. This would be accounted for in the analysis.

- “Yielding a total sample size of approximately 1000 participants”.
  - Does this mean the goal sample size is estimated to be 1000 heel and cord samples?

**Response:**
We have updated this to add ‘...with 1000 heel and 500 cord samples

- “Classification of preterm birth, as well as SGA/AGA/LGA....”
  - Which standards will be used for classification of size for gestation age - is it an international standard like INTERGROWTH-21st or regional standards?

**Response:**
We will use intergrowth-21 standards for gestational age classification, we have added this to the statistical analysis section.
Competing Interests: No competing interests were disclosed.

Reviewer Report 02 November 2020

https://doi.org/10.21956/gatesopenres.14350.r29735

© 2020 Slusher T. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tina M. Slusher
1 Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA
2 Pediatric Critical Care Faculty, Hennepin Healthcare, Minneapolis, MN, USA

I think this article is scientifically sound, well written and easy to follow. The only comments I have are not related to the soundness of the proposal but rather their comments that the metabolic diseases they are choosing to screen for are exceedingly rare - hemoglobinopathies like sickle cell disease are not exceedingly rare and my concerns about how cost effective this would be to sustain after the project in LMICs where it would be most needed. Additionally I would have considered adding G6PD testing to their batteries of tests because although not treatable per se, knowing the infants status is important over their lifetime in terms of medicines they avoid and problems they watch for.

Is the rationale for, and objectives of, the study clearly described?
Yes

Is the study design appropriate for the research question?
Yes

Are sufficient details of the methods provided to allow replication by others?
Yes

Are the datasets clearly presented in a useable and accessible format?
Not applicable

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 10 Nov 2020

Kumanan Wilson, Ottawa Health Research Institute, Ottawa, Canada
Thank you for your review of our article.

We agree with the reviewer that exceedingly should be removed from the manuscript, and we will do this.

The definition of a rare disease varies by country (i.e. US <200,000, Europe, <5 in 10,000). The prevalence of hemoglobinopathies are much higher in African than the rest of the world (10.74 vs. 2.73 per 1000) (Fattoum, Mediter J of Hematol and Infect Dis, 2009).

We have conducted a cost effectiveness analysis (Colyle et al, under review) of our previous study in Bangladesh (Murphy et al, eLife, 2019). This paper is currently under review, and we will add details to the discussion when it is published. There are a number of things to consider when considering different options for preterm birth surveillance including cost and health outcomes. Ultimately the decision about whether to undertake such an initiative will be up to policy makers and global funders. Implementation studies such as this will inform governments and global health funders into the usefulness of these initiatives.

G6PDH is not on the disease panel in Ontario, which is why it was not included in this study.

**Competing Interests:** No competing interests were disclosed.